Reply

We thank Regelmann et al for sharing our interest in this subject and posing important clinical research questions related to medication-induced diabetes mellitus. We acknowledge the heterogeneity of our study population, but point out that our central question was whether there is a new profile of children with medication-induced diabetes in the setting of increased prevalence of overweight and obesity in children in the general population. In this group of 58 children, we did not request the primary disease, but we noted that 98% were receiving at least one diabetogenic drug and 95% were receiving a glucocorticoid. Our hypothesis was that obesity has increased the risk of β-cell exhaustion in these children, leading to a change in the age and ethnicity of affected children. We did not collect C-peptide or insulin levels, because the study was designed as a prospective national incidence surveillance study for non–type 1 diabetes mellitus.